Allison Bratzel
Stock Analyst at Piper Sandler
(4.38)
# 267
Out of 4,944 analysts
39
Total ratings
70%
Success rate
12.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $69.89 | +60.25% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $5.09 | +332.22% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $10.73 | +207.55% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $28.97 | +296.96% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $3.30 | +81.82% | 1 | Mar 14, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $3.68 | +606.52% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $646.60 | +12.12% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $18.05 | +21.88% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $36.58 | -37.12% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $43.10 | +43.85% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $42 | $31.98 | +31.33% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $11.96 | +83.95% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.78 | +124.72% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $6.68 | +199.40% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $4.58 | +336.68% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $85.85 | +16.48% | 2 | Feb 8, 2023 |
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $69.89
Upside: +60.25%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $5.09
Upside: +332.22%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $10.73
Upside: +207.55%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $28.97
Upside: +296.96%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $3.30
Upside: +81.82%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $3.68
Upside: +606.52%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $646.60
Upside: +12.12%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $18.05
Upside: +21.88%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $36.58
Upside: -37.12%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $43.10
Upside: +43.85%
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $31.98
Upside: +31.33%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.96
Upside: +83.95%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.78
Upside: +124.72%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $6.68
Upside: +199.40%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $4.58
Upside: +336.68%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $85.85
Upside: +16.48%